CNR Institutional Research Information System

CERVELLO, MELCHIORRE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.426
NA - Nord America 2.083
EU - Europa 1.102
SA - Sud America 822
AF - Africa 87
OC - Oceania 6
Totale 8.526
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.975
SG - Singapore 1.908
CN - Cina 987
BR - Brasile 675
HK - Hong Kong 544
VN - Vietnam 411
IT - Italia 276
NL - Olanda 262
FR - Francia 251
KR - Corea 178
IN - India 85
GB - Regno Unito 77
JP - Giappone 75
AR - Argentina 58
BD - Bangladesh 52
DE - Germania 47
CA - Canada 43
FI - Finlandia 39
MX - Messico 36
IL - Israele 30
EC - Ecuador 29
ZA - Sudafrica 28
ID - Indonesia 25
ES - Italia 24
TR - Turchia 22
PL - Polonia 19
RU - Federazione Russa 16
IQ - Iraq 15
KE - Kenya 15
SA - Arabia Saudita 15
CO - Colombia 12
MA - Marocco 11
PY - Paraguay 11
SE - Svezia 10
VE - Venezuela 10
AT - Austria 9
CL - Cile 9
PK - Pakistan 9
TN - Tunisia 9
UA - Ucraina 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
JM - Giamaica 8
AZ - Azerbaigian 7
EG - Egitto 7
LV - Lettonia 7
UZ - Uzbekistan 7
CR - Costa Rica 6
LT - Lituania 6
PE - Perù 6
PH - Filippine 6
TW - Taiwan 6
BG - Bulgaria 5
KZ - Kazakistan 5
OM - Oman 5
AU - Australia 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
KH - Cambogia 4
NP - Nepal 4
PT - Portogallo 4
BE - Belgio 3
BO - Bolivia 3
CI - Costa d'Avorio 3
HU - Ungheria 3
IE - Irlanda 3
JO - Giordania 3
MD - Moldavia 3
PA - Panama 3
PS - Palestinian Territory 3
SD - Sudan 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
BB - Barbados 2
BS - Bahamas 2
BY - Bielorussia 2
CH - Svizzera 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GR - Grecia 2
KG - Kirghizistan 2
LU - Lussemburgo 2
NO - Norvegia 2
RE - Reunion 2
RO - Romania 2
SI - Slovenia 2
TH - Thailandia 2
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
IS - Islanda 1
KW - Kuwait 1
LB - Libano 1
MG - Madagascar 1
MK - Macedonia 1
Totale 8.517
Salva come PNG Salva come JPEG
Città #
Singapore 1.129
Santa Clara 742
Hong Kong 539
Hefei 399
San Jose 248
Lauterbourg 206
Seoul 175
Beijing 166
Ho Chi Minh City 145
Ashburn 138
Hanoi 95
Los Angeles 76
Dallas 73
São Paulo 52
Tokyo 49
New York 40
Buffalo 31
Helsinki 28
Minamishinagawa 24
Haiphong 23
Palermo 23
Da Nang 21
Orem 21
Phoenix 20
Wageningen 20
Council Bluffs 19
Mumbai 19
Bengaluru 18
Chennai 18
Frankfurt am Main 17
Brasília 16
Rio de Janeiro 16
Nairobi 15
Atlanta 14
Johannesburg 14
Manchester 14
Mexico City 14
Montreal 14
Thái Bình 14
Belo Horizonte 13
Curitiba 13
Denver 13
Houston 13
Brooklyn 12
Lappeenranta 11
Warsaw 11
Fortaleza 10
Quito 10
Salvador 10
Ankara 9
Dhaka 9
Goiânia 9
Naples 9
Newark 9
Portsmouth 9
Stockholm 9
Elk Grove Village 8
Guayaquil 8
London 8
Montevideo 8
Nuremberg 8
Porto Alegre 8
Biên Hòa 7
Chicago 7
Manaus 7
Ninh Bình 7
Poplar 7
Potenza 7
Riga 7
Riyadh 7
Rome 7
Amsterdam 6
Baku 6
Bologna 6
Boston 6
Cagliari 6
City of London 6
Guangzhou 6
Madrid 6
Nanjing 6
Recife 6
Shanghai 6
Tashkent 6
Toronto 6
Baghdad 5
Bắc Ninh 5
Campinas 5
Casablanca 5
Cavallino 5
Düsseldorf 5
Forest City 5
Istanbul 5
Kingston 5
Lima 5
Milan 5
New Delhi 5
Osasco 5
San Francisco 5
Santiago 5
Seeb 5
Totale 5.153
Salva come PNG Salva come JPEG
Nome #
Photoaging of polystyrene-based microplastics amplifies inflammatory response in macrophages 154
The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods 97
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 97
The clinical impact of an extra virgin olive oil enriched mediterranean diet on metabolic syndrome: Lights and shadows of a nutraceutical approach 97
Potential uses of olive oil secoiridoids for the prevention and treatment of cancer: A narrative review of preclinical studies 95
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells 93
Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation 84
New landscapes and horizons in hepatocellular carcinoma therapy. 83
Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta 83
Cationic Solid-lipid nanoparticles as DNA carriers. 79
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells 76
Spatial distribution of collagene TypeI mRNA in Paracentrotus lividus eggs and embryos. 73
Advances in targeting signal transduction pathways. 71
A BDE-47/estrone mixture modulates macrophage immune responses and miRNA networks, impairs intestinal barrier integrity in vitro, and alters circulating miRNAs and tight junction expression in vivo 70
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. 68
The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH 68
Antitumor effects of curcumin and its combination with cisplatin or doxorubicin on hepatic cancer cells: possible relationship to NF-kB activation and IAP gne expression 66
The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma 64
TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors 64
Cancer therapy and treatments during COVID-19 era 63
New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells 63
New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways 61
COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. 61
RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma 61
Cationic solid lipid nanoparticles complexed with genetic material for liver tumor treatment 61
Gene expression profiling of MCF10A breast epithelial cells exposed to IOERT 60
The novel NF-kB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. 58
Magnetic Nanoparticles tailored with Peptides/Amphiphilic Cyclodextrins assemblies: from Amyloid- detection to theranostic applications. 57
NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response 57
Gamma enolase expression as early marker of neuronal differentiation of murine neuroblastoma cells N-115 55
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines 53
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells 53
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression 52
Hepatocellular Carcinoma: A Difficult Cancer to Treat 52
GSK-3 in liver diseases: Friend or foe? 52
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53 52
Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis 52
Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. 51
Abilities of ?-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells 51
Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy 50
The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment 50
Nanoparticelle lipidiche solide cationiche come vettori del DNA. 49
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer 49
Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma 49
Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population 49
Epidemiology, risk factors, and natural history of hepatocellular carcinoma 49
Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis 48
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway 47
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling 47
Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53 47
Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment 47
Extracellular Vesicle-Related Non-Coding RNAs in Hepatocellular Carcinoma: An Overview 47
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals 46
Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies 46
Lipid nanocarriers containing sorafenib inhibit colonies formation into human hepatocarcinoma cells 46
Development of nimesulide loaded solid lipid nanoparticles. 46
Emerging Use of Nanotechnology for the Treatment of Liver Diseases 45
Cationic Solid Lipid Nanoparticles as Non Viral Vectors for the Inhibition of Hepatocellular Carcinoma Growth by RNA Interference 45
Expression of HIP/PAP mrna in human hepatoma cell lines 44
GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals 44
Synthetic peptide-labelled micelles for active targeting of cells overexpressing EGF receptors 44
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma 44
Preface: Advances in molecular targets for therapeutics in resistant cancers 43
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. 42
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells 42
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals 42
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells 41
Aromatase and amphiregulin are correspondingly espressed in human liver cancer cells. 40
Emerging Raf inhibitors. 40
Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma 40
Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53 40
Can Baseline IL-6 Levels Predict Long COVID in Subjects Hospitalized for SARS-CoV-2 Disease? 40
Association Between MICA Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample 39
Non invasive tools for the diagnosis of liver cirrhosis 38
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. 38
Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells 38
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. 38
Roles of proliferative and metastatic pathways in chemotherapeutic drug resistance and cancer stem cells-sites for therapeutic intervention 37
Structure-based identification of a non-covalent thioredoxin reductase inhibitor with proven ADMET suitability 37
Sex hormones and risk of liver tumor. 37
Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-±, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma. 37
Phosphorylation-dependent regulation of skeletogenesis in sea urchin micromere-derived cells and embryos. 36
Effects of ectopic expression of NGAL on doxorubicin sensitivity 36
Antitumor effects of DHMEQ, a novel NF-kB inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. 36
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. 36
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 35
Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression 34
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 34
Targeting the cancer initiating cell: The ultimate target for cancer therapy 34
Cationic solid-lipid nanoparticles for gene delivery. 34
GDF11 induces mild hepatic fibrosis independent of metabolic health 33
Molecular mechanisms of sorafenib action in liver cancer cells. 33
Antitumor effects of curcumin and its combination with cisplatin or doxorubicin on hepatic cancer cells: possible relationship to NF-kB activation and IAP gne expression. 32
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 32
From targets to targeted therapies in Hepatocellular carcinoma 32
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells. 32
Cyclooxygenases in cancer 32
Microgravity and cellular homeostasis: effects of simulated hypogravity on FRTL-5 thyroid cells. 32
Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery 31
Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation 31
Totale 5.169
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.494
article - articoli 20.320
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 607
Totale 48.421
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202422 0 0 0 0 0 0 0 0 1 0 13 8
2024/20253.347 38 26 243 138 658 141 44 144 84 261 867 703
2025/20265.232 282 485 505 956 945 166 724 348 308 291 222 0
Totale 8.601